Stoesser Nicole, Sheppard Anna E, Peirano Gisele, Sebra Robert P, Lynch Tarah, Anson Luke W, Kasarskis Andrew, Motyl Mary R, Crook Derrick W, Pitout Johann D
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5068-71. doi: 10.1128/AAC.00840-16. Print 2016 Aug.
The blaIMP-14 carbapenem resistance gene has largely previously been observed in Pseudomonas aeruginosa and Acinetobacter spp. As part of global surveillance and sequencing of carbapenem-resistant Escherichia coli, we identified a sequence type 131 strain harboring blaIMP-14 within a class 1 integron, itself nested within an ∼54-kb multidrug resistance region on an epidemic IncA/C2 plasmid. The emergence of blaIMP-14 in this context in the ST131 lineage is of potential clinical concern.
blaIMP-14碳青霉烯耐药基因此前主要在铜绿假单胞菌和不动杆菌属中被发现。作为全球耐碳青霉烯类大肠杆菌监测和测序的一部分,我们鉴定出一株序列型131菌株,其在1类整合子中携带blaIMP-14,该整合子本身嵌套在一个流行的IncA/C2质粒上约54kb的多药耐药区域内。在ST131菌系的这种情况下blaIMP-14的出现具有潜在的临床意义。